RWJ-67657 NEW
| Price | $39 | $64 | $97 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-18 |
Product Details
| Product Name: RWJ-67657 | CAS No.: 215303-72-3 |
| Purity: 99.66% | Supply Ability: 10g |
| Release date: 2024/11/18 |
Product Introduction
Bioactivity
| 名稱 | RWJ-67657 |
| 描述 | RWJ-67657 (JNJ 3026582) is an orally active, selective p38α and p38β MAPK inhibitor (IC50s: 1 and 11 μM, respectively), with no activity at p38γ and p38δ, and demonstrates cardioprotective effects. |
| 體外活性 | RWJ-67657 suppresses the release of TNF-α by lipopolysaccharide (LPS)-treated human peripheral blood mononuclear cells (IC50: 3 nM) and the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (IC50: 13 nM). RWJ67657 (10 μM; 24 hours) reduces colony formation in MCF-7 cells [2][3]. |
| 體內(nèi)活性 | RWJ-67657 inhibits TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration. RWJ-67657 (50 mg/kg; p.o.; once daily for 7 consecutive days) demonstrates effective anti-inflammatory activity. EPC transplantation combined with RWJ-67657 administration synergistically promotes angiogenesis and neurogenesis following diabetic stroke by enhancing endothelial progenitor cell function and reducing inflammation [2][4]. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 125 mg/mL (293.77 mM), Sonication and heating to 60℃ are recommended. |
| 關(guān)鍵字 | RWJ-67657 | RWJ67657 | p38 MAPK | RWJ 67657 | Inhibitor | JNJ3026582 | anti-tumor | JNJ-3026582 | p38α | protective. Anti-inflammatory | MCF-7 | inhibit | inflammation | cardio | p38β |
| 相關(guān)產(chǎn)品 | Adezmapimod | Doramapimod | Dihydrocaffeic acid | VX-702 | Bakuchiol | p38α inhibitor 3 | SB 202190 | (-)-Bornyl acetate | MW-150 | Allicin | (E)-Ferulic acid methyl ester | p38-α MAPK-IN-1 |
| 相關(guān)庫 | 經(jīng)典已知活性庫 | 疼痛相關(guān)化合物庫 | 激酶抑制劑庫 | 抗肥胖化合物庫 | 抑制劑庫 | 口服活性化合物庫 | 抗衰老化合物庫 | 已知活性化合物庫 | 抗癌化合物庫 | 抗癌活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $159.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-16 | |
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-09-28 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY